JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report), ...
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
BioPharma Dive14h
Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
BioSpace16h
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.
Barclays Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
Barclays analyst Gena Wang maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of ...
Solid Biosciences Shares Rise After Positive Trial Data for SGT-003 in Duchenne MD
Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...
PCGamesN21h
Where to buy 5090 - Nvidia RTX 5090 stock for February 18
In this guide, you’ll find links to stores around the world that have either stock notifications, pre-orders, or actual stock available and we update it every day, to see if new stock has ...